Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line

Fig. 1

Scheme of drug combinations and their analysis. A Each drug was serially diluted by 3.5-fold. Then, two drugs in an equimolar concentration were mixed and treated to cells for combination. B 12 drugs, two drugs each in 6 different drug classes, were used for combination. 6 different doses of the equimolar drug mix were treated to cells individually. Then, cells were imaged under microscope by 3 different channels at 4 different timepoints. C Cells were directly counted from cell images by Nikon Eclipse software. Then, growth rate and synergy score were calculated from cell numbers for drug synergy screen. Cell images were also used for HS analysis, which included background subtraction, cell segmentation, and feature extraction. Phenotypic profiles were analyzed by KS statistics and LDA for KNN assignment, which allowed us to determine how individual drugs contributed to combination drug responses

Back to article page